Business Context and Reporting Period
Company: Kura Oncology, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 28, 2026
Event: Adoption of Amended and Restated Bylaws by the Board of Directors.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a corporate governance report regarding bylaw amendments.
Material Changes
The Board adopted amended and restated bylaws effective January 28, 2026. Key changes include:
- Stockholder Nominations: Stockholders must be record holders at the time of the annual meeting (in addition to the notice date) to nominate directors. Limits were placed on the number of nominees, and substitute nominees are prohibited without timely notice.
- Meeting Procedures: Clarified authority to postpone, reschedule, or cancel meetings. The alternative window for determining timely notice of proposals now applies if the meeting date is advanced by more than 30 days or delayed by more than 70 days (previously 30 days).
- Voting Thresholds:
- Quorum: Changed from a majority of outstanding shares to a majority of voting power of outstanding shares.
- Proposal Approval: Changed from a majority of shares present to a majority of votes cast (excluding abstentions and broker non-votes).
- Adjournment: Changed from a majority of shares present to a majority of votes cast.
- Indemnification: Expanded mandatory obligations to indemnify directors and officers to the maximum extent allowed by law. Clarified procedures for advancing expenses.
- Forum Selection: Enhanced provisions to designate Delaware federal courts as a backup forum to Delaware state courts and added a forum selection bylaw for Securities Act of 1933 claims.
- Universal Proxy: Incorporated procedures consistent with Rule 14a-19.
Guidance, Outlook, and Risks
This filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary risk implication relates to corporate governance, specifically stricter requirements for stockholder proposals and director nominations, and the expansion of indemnification protections for directors and officers.
Key Facts for Investor Verification
- Verify the full text of the Amended and Restated Bylaws attached as Exhibit 3.1 (referenced as Exhibit 99.1 in the summary table) for complete legal language.
- Confirm the impact of the new "majority of votes cast" standard on future shareholder proposal outcomes.
- Note the expanded indemnification and expense advancement rights for directors and officers.
- Review the new requirement for stockholders to be record holders at the time of the annual meeting to nominate directors.